Information
- ID of tender
-
4316
- Name of content of tender
-
LIEKY pre potreby Fakultnej nemocnice s poliklinikou F. D. Roosevelta Banská Bystrica č. 792/2019 v rozsahu IMMUNOPREPARÁTA – Antineoplastické a imunomodulačné činidlá; CYTOSTATIKÁ – Antineoplastické činidlá
- Tender ref. no.
-
RVO/792/2019
- Public tender journal ref. no.
-
Vestník č. 144/2019, 18205-MST, z 19.07.2019
- EU journal ref. no.
-
2019/S 137-336827
- Type of tender
-
Nadlimitná zákazka
- Type of public tender
-
Verejná súťaž podľa § 66 (7)
- Type of procurement
-
Goods
- Estimated value
-
5 972 371,9400 EUR
- Main CPV
-
33600000-6 - Pharmaceutical products
- Further CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
33652100-6 - Antineoplastic agents
- Tender split into parts
- Yes
- Centralised tender
-
No
- NUTS
-
SK - Slovenská republika
- Brief description of tender or procurement
-
Predmetom zákazky je dodávka „LIEKOV pre potreby Fakultnej nemocnice s poliklinikou F. D. Roosevelta Banská Bystrica č. 792/2019 v rozsahu IMMUNOPREPARÁTA – Antineoplastické a imunomodulačné činidlá; CYTOSTATIKÁ – Antineoplastické činidlá“ verejným obstarávateľom požadovanej špecifikácie, vrátane dodania na miesto určenia.
3.1. Predmet zákazky je rozdelený na častí. Uchádzačovi sa umožňuje predložiť ponuku na celý predmet zákazky - na všetkých 48 častí, alebo len na jednu časť predmetu zákazky alebo na viacero častí predmetu zákazky, špecifikovaných v bode „ B – Opis predmetu zákazky „ týchto súťažných podkladov.
- For evaluation the price is determined
-
including VAT
Schedule
-
Lehota na predkladanie ponúk
-
26.08.2019 10:00:00
-
Planned opening of bids
-
26.08.2019 14:00:00
Documents
Name of document
|
Type
|
Size
|
Uploaded on
|
|
Súťažné podklady
|
Súťažné podklady
|
1.83 MB
|
18.07.2019 12:37:33
|
|
Súťažné podklady - Obchodné podmienky - Návrh RZ
|
Súťažné podklady
|
34.88 KB
|
18.07.2019 12:36:15
|
|
JED-formulár
|
Súťažné podklady
|
625.46 KB
|
15.07.2019 08:10:35
|
|
Príoha č. 1. - Cenová ponuka k RZ
|
Súťažné podklady
|
409.76 KB
|
15.07.2019 08:10:05
|
|
Príloha č. 1. k RD - Cenová ponuka k RZ
|
Súťažné podklady
|
332.81 KB
|
15.07.2019 08:07:38
|
|
Príloha č. 2 k SP - G. Tabuľka návrhov na plnenie kritérií
|
Súťažné podklady
|
24.82 KB
|
15.07.2019 08:05:59
|
|
Príloha č. 2 k SP - G. Tabuľka návrhov na plnenie kritérií
|
Súťažné podklady
|
274.35 KB
|
15.07.2019 08:05:30
|
|
Príloha č. 1 k SP - Opis predmetu zákazky
|
Súťažné podklady
|
34.48 KB
|
15.07.2019 08:04:56
|
|
Príloha č. 1 k SP - Opis predmetu zákazky
|
Súťažné podklady
|
264.65 KB
|
15.07.2019 08:04:23
|
|
Časť č. 1. Immunoglobulinum humanum
- Status
-
Completed
- Predicted value not including VAT
-
257 871,3600 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement
Časť č. 2. Albuminum humanum
- Status
-
Completed
- Predicted value not including VAT
-
320 502,3600 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement
Časť č. 3. Albuminum humanum
- Status
-
Completed
- Predicted value not including VAT
-
51 034,2000 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement
Časť č. 4. Mofetilis mycophenolas tbl flm alebo tbl ent alebo cps dur 500mg
- Status
-
Completed
- Predicted value not including VAT
-
5 575,6800 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement
Časť č. 5. Filgrastimum sol ijf alebo sol irs 0,5ml/48MU
- Status
-
Completed
- Predicted value not including VAT
-
15 582,0000 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement
Časť č. 6. Filgrastimum sol ijf 0,8ml/48MIU
- Status
-
Completed
- Predicted value not including VAT
-
5 319,2400 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement
Časť č. 7. Ciclosporinum
- Status
-
Completed
- Predicted value not including VAT
-
3 062,1000 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement
Časť č. 8. Rituximabum
- Status
-
Completed
- Predicted value not including VAT
-
29 115,8400 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement
Časť č. 9. Infliximabum plc ifc 100mg/10ml
- Status
-
Completed
- Predicted value not including VAT
-
327 668,0000 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement
Časť č. 10. Králičí imunoglobulín proti ľudským tymocytom plv ifo 25mg/ 5 ml
- Status
-
Completed
- Predicted value not including VAT
-
296 144,0000 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement
časť č. 11. Belimumab
- Status
-
Completed
- Predicted value not including VAT
-
157 740,0000 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement
Časť č. 12. Takrolimu
- Status
-
Completed
- Predicted value not including VAT
-
41 174,4000 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement
Časť č. 13. Acidum mycofenolicum
- Status
-
Completed
- Predicted value not including VAT
-
9 410,6000 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement
Časť č. 14. Immunoglobulinum humanum Anti-D Rh sol inj 1 250 IU/ 2ml alebo 1 500 IU/ 2ml
- Status
-
Completed
- Predicted value not including VAT
-
10 437,9000 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement
Časť č. 15. Immunoglobulinum humanum normale
- Status
-
Completed
- Predicted value not including VAT
-
8 392,4200 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement
Časť č. 16. Abatacept plc ifc 250mg
- Status
-
Completed
- Predicted value not including VAT
-
122 080,0000 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement
Časť č. 17. Basiliximab plv iio 20 mg
- Status
-
Completed
- Predicted value not including VAT
-
173 600,0000 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement
Časť č. 18. Rekombinantný interferón beta-1b plv iol 1,2ml /300 ug
- Status
-
Completed
- Predicted value not including VAT
-
34 498,0000 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement
Časť č. 19. Anatoxinum tetanicum purificatum sus inj 0,5ml/40 IU
- Status
-
Completed
- Predicted value not including VAT
-
613,8000 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement
Časť č. 20. Plerixaforum sol inj 1,2ml/24mg
- Status
-
Completed
- Predicted value not including VAT
-
25 800,0000 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement
ČaSť č. 21. Ekulizumabum con inf 30ml/300mg
- Status
-
Completed
- Predicted value not including VAT
-
626 666,0400 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement
Časť č. 22. Peginterferó beta-1a sol inj 0,5ml/125ug pero
- Status
-
Completed
- Predicted value not including VAT
-
60 650,0000 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement
Časť č. 23. Natalizumabum con inf 15ml/300mg
- Status
-
Completed
- Predicted value not including VAT
-
80 343,1200 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement
Časť č. 24. Vedolizumabum plc ifc 300mg
- Status
-
Completed
- Predicted value not including VAT
-
339 616,4000 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement
Časť č. 25. Alemtuzumabum con inf 1,2ml/12mg
- Status
-
Completed
- Predicted value not including VAT
-
227 568,3200 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement
Časť č. 26. Ustekinumabum
- Status
-
Completed
- Predicted value not including VAT
-
130 750,0400 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement
Časť č. 27. Proteinum plasmatis humani sol inf 200ml/ 9 - 14g
- Status
-
Completed
- Predicted value not including VAT
-
1 661,5200 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement
Časť č. 28. Lyofilizovaný dialyzát leukocytov plv iol 4ml/ 200 miliónov leukocytov
- Status
-
Completed
- Predicted value not including VAT
-
12 018,0800 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement
Časť č. 29. Mycophenolatum mofetilum plc ifc 500mg
- Status
-
Completed
- Predicted value not including VAT
-
249,2000 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement
Časť č. 30. Bacillus Calmette-Guérin baktérie plv suf
- Status
-
Completed
- Predicted value not including VAT
-
27 841,6600 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement
Časť č. 31. Azatioprínum tbl flm 50mg
- Status
-
Completed
- Predicted value not including VAT
-
291,9800 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement
Časť č. 32. Sirolimus tbl obd 1mg
- Status
-
Completed
- Predicted value not including VAT
-
1 887,0000 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement
Časť č. 33.Azoximeri bromidum lyo ijo 6mg
- Status
-
Completed
- Predicted value not including VAT
-
638,3200 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement
Časť č. 34. Okrelizumabum con inf 10ml/300mg
- Status
-
Completed
- Predicted value not including VAT
-
145 658,5600 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652000-5 - Antineoplastic and immunomodulating agents
- Outcome of tender
- Framework Agreement
Časť. 35. Cetuximabum sol inf 20ml/100mg
- Status
-
Completed
- Predicted value not including VAT
-
445 176,0000 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652100-6 - Antineoplastic agents
- Outcome of tender
- Framework Agreement
Časť č. 36. Panitumumabum
- Status
-
Completed
- Predicted value not including VAT
-
3 485,4600 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652100-6 - Antineoplastic agents
- Outcome of tender
- Framework Agreement
Časť č. 37. Dabrafenibum cps dur 75mg
- Status
-
Completed
- Predicted value not including VAT
-
49 059,4000 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652100-6 - Antineoplastic agents
- Outcome of tender
- Framework Agreement
Časť č. 38. Pemrolizumabum con inf 4ml/100mg
- Status
-
Completed
- Predicted value not including VAT
-
1 579 446,0800 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652100-6 - Antineoplastic agents
- Outcome of tender
- Framework Agreement
Časť č. 39. Krizotinib
- Status
-
Completed
- Predicted value not including VAT
-
58 218,6000 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652100-6 - Antineoplastic agents
- Outcome of tender
- Framework Agreement
Časť č. 40. Osimertinib tbl flm 80mg
- Status
-
Completed
- Predicted value not including VAT
-
9 067,9000 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652100-6 - Antineoplastic agents
- Outcome of tender
- Framework Agreement
Časť č. 41. Trifluridín
- Status
-
Completed
- Predicted value not including VAT
-
158 616,4000 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652100-6 - Antineoplastic agents
- Outcome of tender
- Framework Agreement
Časť č. 42. Cytarabinum
- Status
-
Completed
- Predicted value not including VAT
-
15 251,3600 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652100-6 - Antineoplastic agents
- Outcome of tender
- Framework Agreement
Časť č. 43. Oxaliplatina
- Status
-
Completed
- Predicted value not including VAT
-
23 104,0000 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652100-6 - Antineoplastic agents
- Outcome of tender
- Framework Agreement
Časť č. 44. Paklitaxel
- Status
-
Completed
- Predicted value not including VAT
-
27 822,6800 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652100-6 - Antineoplastic agents
- Outcome of tender
- Framework Agreement
Časť č.45. Ramucirumabum con inf 10 ml/100 mg
- Status
-
Completed
- Predicted value not including VAT
-
23 660,2800 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652100-6 - Antineoplastic agents
- Outcome of tender
- Framework Agreement
Časť č. 46. Vinorelbinum con inf 50 mg/5ml
- Status
-
Completed
- Predicted value not including VAT
-
14 565,6600 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652100-6 - Antineoplastic agents
- Outcome of tender
- Framework Agreement
Časť č. 47. Vinorelbinum con inf 50 mg/5ml v SPC registrovaná indikácia karcinóm prsníka a karcinóm prostaty
- Status
-
Completed
- Predicted value not including VAT
-
6 024,5400 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652100-6 - Antineoplastic agents
- Outcome of tender
- Framework Agreement
Časť č. 48. Trastuzumabum plc ifc 150 mg
- Status
-
Completed
- Predicted value not including VAT
-
7 411,4400 EUR
- Criterion for evaluation of bid
-
Lowest price
- Electronic auction
-
Yes
- Main CPV
-
33652100-6 - Antineoplastic agents
- Outcome of tender
- Framework Agreement